Medgenome Partners with Twist Teams in India to Diagnose Rare Disease

Medgenome Partners with Twist Teams in India to Diagnose Rare Disease

By, Admin 27 September 2024

Overview

MedGenome, a leading global genomics-driven diagnostics and research services company is partnering with Twist Bioscience, a leading and rapidly growing synthetic biology and genomics company based in the US, to establish the HOPE for Rare Diseases Programme in India. Within the programme, discounted whole exome sequencing is provided to the patients from economically disadvantaged families (with necessary documentation) and is a time limited programme.

Collab for Affordable Genetic Solutions

  • The collaboration coincides with MedGenome’s commemoration of a decade of pioneering genomics advancements in India. 
  • With this partnership, MedGenome reaffirms its commitment to democratize access to quality and affordable genetic solutions for all sections of society. 
  • MedGenome will continue to be guided by its vision to enhance healthcare affordability and accessibility and focus on its mission to leverage genomics to address the huge unmet need across emerging markets.

Twist Exome 2.0

  • Twist Bioscience is deploying the Twist Exome 2.0 to support this mission. 
  • Designed to enable researchers to detect rare and inherited diseases, as well as germline cancers, supporting researchers and clinicians in their ability to collect quality data with less sequencing.

Aim of Collaboration

The partnership between MedGenome and Twist Bioscience is to bring this technology to economically disadvantaged people in the world, providing the genetic information they need to end their diagnostic odysseys and help clinicians pursue the management and treatment of the disease.

For Cost-Efficient Healthcare in India

  • Although this technology has been available for over a decade, it has not gained significant traction due to its cost, limited awareness, and the lack of insurance coverage, as healthcare in India remains an out-of-pocket expense. 
  • The HOPE for Rare Diseases Programme, established in August 2024 aims to address this issue and provide whole exome sequencing for impoverished rare disease patients.

Rare Genetic Diseases

  • Rare genetic diseases are far from rare. 
  • By definition, each individual disease affects fewer than 200,000 people; however, there are more than 7,000 of these often-debilitating conditions. In the US, around 25 million people are affected. 
  • In India, this number is even higher, at least 70 million, many of them children.
  • People contending with rare diseases often face lengthy odysseys as clinicians try to find a diagnosis. 
  • While the symptoms are often obvious, clinicians may not have the precise tools to identify the exact disease, its underlying causes or potential treatments. 
  • This uncertainty can go on for months or even years.

Genomic Sequencing Impacts

  • Genomic sequencing has helped address this challenge for clinicians. 
  • Whole exome sequencing focuses on protein-coding genes to find the genetic variants that may be causing each patient’s specific condition, information that could suggest potential management and treatment options.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!